Limits...
The Clinical Importance of the Heterogeneity of HER2 neu.

Davila E, Amazon K - Case Rep Oncol (2010)

Bottom Line: Depending on the area tested the results were completely different.The clinical implications are important.We recommend retesting a large portion of the tumor in all cases of initially negative test results.

View Article: PubMed Central - PubMed

Affiliation: Aventura Comprehensive Cancer Center, Aventura, Fla., USA.

ABSTRACT
We report on a patient with breast cancer in whom there were areas of the tumor that were 3+ positive and negative for HER2 neu by immunohistochemistry, adjacent to each other. Depending on the area tested the results were completely different. The clinical implications are important. We recommend retesting a large portion of the tumor in all cases of initially negative test results.

No MeSH data available.


Related in: MedlinePlus

Amplification of small square in figure 1. Junction between HER2-positive and -negative zones.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC2968767&req=5

Figure 2: Amplification of small square in figure 1. Junction between HER2-positive and -negative zones.

Mentions: The histopathology of the tumor was reviewed again, attempting to explain the disparity of the results, and we found that the majority of tumor cells expressing 3+ positivity for HER2 neu by IHC were surrounding a defined area of the same histologic tumor that was negative for HER2 neu, by the same IHC. Fig. 1 shows a whole mount of the tumor on a glass slide stained with IHC for HER2 neu, showing malignant cells expressing 3+ positivity for HER2 neu adjacent to negative expression. Furthermore, in the area of HER2 neu negativity, we were able to identify the needle tract left by the biopsy needle (schematically represented by two parallel lines), and a small square was amplified to higher power showing the junction between HER2-positive and -negative zones (fig. 2).


The Clinical Importance of the Heterogeneity of HER2 neu.

Davila E, Amazon K - Case Rep Oncol (2010)

Amplification of small square in figure 1. Junction between HER2-positive and -negative zones.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC2968767&req=5

Figure 2: Amplification of small square in figure 1. Junction between HER2-positive and -negative zones.
Mentions: The histopathology of the tumor was reviewed again, attempting to explain the disparity of the results, and we found that the majority of tumor cells expressing 3+ positivity for HER2 neu by IHC were surrounding a defined area of the same histologic tumor that was negative for HER2 neu, by the same IHC. Fig. 1 shows a whole mount of the tumor on a glass slide stained with IHC for HER2 neu, showing malignant cells expressing 3+ positivity for HER2 neu adjacent to negative expression. Furthermore, in the area of HER2 neu negativity, we were able to identify the needle tract left by the biopsy needle (schematically represented by two parallel lines), and a small square was amplified to higher power showing the junction between HER2-positive and -negative zones (fig. 2).

Bottom Line: Depending on the area tested the results were completely different.The clinical implications are important.We recommend retesting a large portion of the tumor in all cases of initially negative test results.

View Article: PubMed Central - PubMed

Affiliation: Aventura Comprehensive Cancer Center, Aventura, Fla., USA.

ABSTRACT
We report on a patient with breast cancer in whom there were areas of the tumor that were 3+ positive and negative for HER2 neu by immunohistochemistry, adjacent to each other. Depending on the area tested the results were completely different. The clinical implications are important. We recommend retesting a large portion of the tumor in all cases of initially negative test results.

No MeSH data available.


Related in: MedlinePlus